Christopher M. Loughrey

University Place
Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Optimized murine HFpEF models for translational preclinical studies.

Optimized murine HFpEF models for translational preclinical studies.

Journal: ESC heart failure

Published: September 29, 2025

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.

Journal: Cardiovascular research

Published: June 24, 2025

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.

Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.

Journal: Cardiovascular research

Published: June 24, 2025

The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD+ Therapy in HFpEF.

The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD+ Therapy in HFpEF.

Journal: Circulation research

Published: April 11, 2025

Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation.

Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation.

Journal: The Journal of pharmacology and experimental therapeutics

Published: April 05, 2025

A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.

A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.

Journal: British journal of pharmacology

Published: October 12, 2023

Ribonucleicacid interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction.

Ribonucleicacid interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction.

Journal: Cardiovascular research

Published: January 13, 2023

Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size.

Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size.

Journal: Cardiovascular research

Published: May 14, 2021

Preclinical models of myocardial infarction: from mechanism to translation.

Preclinical models of myocardial infarction: from mechanism to translation.

Journal: British journal of pharmacology

Published: February 04, 2021

Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling.

Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling.

Journal: Cellular signalling

Published: July 09, 2020

Displacement Encoding With Stimulated Echoes Enables the Identification of Infarct Transmurality Early Postmyocardial Infarction.

Displacement Encoding With Stimulated Echoes Enables the Identification of Infarct Transmurality Early Postmyocardial Infarction.

Journal: Journal of magnetic resonance imaging : JMRI

Published: April 06, 2020

RUNX1: an emerging therapeutic target for cardiovascular disease.

RUNX1: an emerging therapeutic target for cardiovascular disease.

Journal: Cardiovascular research

Published: September 30, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026